Maria Schubert1,2, Kerstin Junker3, Joana Heinzelmann4. 1. Department of Clinical Andrology, Center of Reproductive Medicine and Andrology, University Hospital Muenster, Domagkstr. 11, 48149, Muenster, Germany. 2. Department of Urology and Pediatric Urology, Comprehensive Cancer Center (CCC) Mainfranken, University Hospital Wuerzburg, Oberduerrbacher Straße 6, 97080, Würzburg, Germany. 3. Clinic of Urology and Pediatric Urology, Saarland University Medical Center, Kirrberger Strasse 1, 66424, Homburg/Saar, Germany. kerstin.junker@uks.eu. 4. Clinic of Urology and Pediatric Urology, Saarland University Medical Center, Kirrberger Strasse 1, 66424, Homburg/Saar, Germany.
Abstract
PURPOSE: Defining reliable biomarkers is still a challenge in patients with urological tumors. Because miRNAs regulate diverse important cellular processes, these noncoding RNAs are putative molecular candidates. This review intends to give a critical overview about the current state of miRNAs as biomarkers in urological cancers with respect to prognostic stratification as well as for individual treatment selection. METHODS: A comprehensive review of the published literature was conducted focusing at the clinical relevance of miRNAs in tissues and body fluids of prostate, bladder and kidney cancer. Using electronic database, 91 articles, published between 2009 and 2015, were selected and discussed regarding the robustness of miRNAs as valid biomarkers. RESULTS: A number of miRNAs have been identified with prognostic and predictive relevance in different urologic tumor types. However, the inconsistency of the published results and the lack of multivariate testing in independent cohorts do not allow an introduction into clinical decision making at present. CONCLUSION: miRNA-based biomarkers are a promising tool for future personalized risk stratification and response prediction in urological cancers.
PURPOSE: Defining reliable biomarkers is still a challenge in patients with urological tumors. Because miRNAs regulate diverse important cellular processes, these noncoding RNAs are putative molecular candidates. This review intends to give a critical overview about the current state of miRNAs as biomarkers in urological cancers with respect to prognostic stratification as well as for individual treatment selection. METHODS: A comprehensive review of the published literature was conducted focusing at the clinical relevance of miRNAs in tissues and body fluids of prostate, bladder and kidney cancer. Using electronic database, 91 articles, published between 2009 and 2015, were selected and discussed regarding the robustness of miRNAs as valid biomarkers. RESULTS: A number of miRNAs have been identified with prognostic and predictive relevance in different urologic tumor types. However, the inconsistency of the published results and the lack of multivariate testing in independent cohorts do not allow an introduction into clinical decision making at present. CONCLUSION: miRNA-based biomarkers are a promising tool for future personalized risk stratification and response prediction in urological cancers.
Authors: Martin Hart; Elke Nolte; Sven Wach; Jaroslaw Szczyrba; Helge Taubert; Tilman T Rau; Arndt Hartmann; Friedrich A Grässer; Bernd Wullich Journal: Mol Cancer Res Date: 2013-12-13 Impact factor: 5.852
Authors: Heba W Z Khella; Andreas Scorilas; Roy Mozes; Lorna Mirham; Evi Lianidou; Sergey N Krylov; Jason Y Lee; Michael Ordon; Robert Stewart; Michael A S Jewett; George M Yousef Journal: Am J Pathol Date: 2015-01-05 Impact factor: 4.307
Authors: James W F Catto; Saiful Miah; Helen C Owen; Helen Bryant; Katie Myers; Ewa Dudziec; Stéphane Larré; Marta Milo; Ishtiaq Rehman; Derek J Rosario; Erica Di Martino; Margaret A Knowles; Mark Meuth; Adrian L Harris; Freddie C Hamdy Journal: Cancer Res Date: 2009-10-20 Impact factor: 12.701
Authors: Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley Journal: Nat Cell Biol Date: 2011-03-20 Impact factor: 28.824
Authors: Angeline S Andrew; Margaret R Karagas; Florian R Schroeck; Carmen J Marsit; Alan R Schned; Jason R Pettus; David A Armstrong; John D Seigne Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-01-30 Impact factor: 4.254
Authors: Vito Cucchiara; Joy C Yang; Vincenzo Mirone; Allen C Gao; Michael G Rosenfeld; Christopher P Evans Journal: Cancers (Basel) Date: 2017-01-16 Impact factor: 6.639
Authors: Zixu Yuan; Kelsey Baker; Mary W Redman; Lei Wang; Scott V Adams; Ming Yu; Brandon Dickinson; Karen Makar; Neli Ulrich; Jürgen Böhm; Michelle Wurscher; Maria Westerhoff; Steve Medwell; Ravi Moonka; Mika Sinanan; Alessandro Fichera; Kathy Vickers; William M Grady Journal: Br J Cancer Date: 2017-08-15 Impact factor: 7.640